Evotec SE
NASDAQ: EVO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Christian Wojczewski
- Employees
- 4,766
- Headquarters
- Hamburg, Germany
- IPO year
- 2004
- Market cap
- $955.5M
- Website
- https://www.evotec.com
Loading EVO…
Loading profile data…Frequently asked questions about EVO
What does Evotec SE (EVO) do?
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complication...
Where does EVO trade?
Evotec SE (EVO) trades on the NASDAQ Global Select.
What sector is EVO in?
Evotec SE (EVO) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Evotec SE?
Christian Wojczewski is the chief executive officer of Evotec SE (EVO).
Where is Evotec SE headquartered?
Evotec SE is headquartered in Germany.
Does EVO pay a dividend?
Evotec SE (EVO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EVO go public?
Evotec SE (EVO) completed its initial public offering in 2004.
Is EVO an ADR?
Yes — EVO is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Evotec SE reporting and dividends follow the underlying issuer.